Dr. Sharma on Results of SIRFLOX Study for CRC

Navesh K. Sharma, DO, PhD
Published: Wednesday, Jul 13, 2016


Navesh K. Sharma, DO, PhD, associate professor of Radiology, Division of Radiology and Oncology, Penn State Hershey Medical Center, section chief of Radiation Oncology, Penn State Health St. Joseph Cancer Center, discusses the results of the SIRFLOX study, which examined the addition of selective internal radiation therapy (SIRT) with SIR-Spheres Y-90 resin microspheres to standard frontline FOLFOX-based chemotherapy with or without bevacizumab (Avastin) for patients with liver metastatic colorectal cancer (CRC).

Although researchers are still awaiting data on overall survival, findings thus far demonstrate that the addition improves liver disease, leading to a significant improvement in progression-free survival. This is important because, Sharma adds, this is the most common site of metastasis in patients with CRC.

Secondly, the addition of SIRT was also found to be safe and well tolerated in this patient population, Sharma explains.

Navesh K. Sharma, DO, PhD, associate professor of Radiology, Division of Radiology and Oncology, Penn State Hershey Medical Center, section chief of Radiation Oncology, Penn State Health St. Joseph Cancer Center, discusses the results of the SIRFLOX study, which examined the addition of selective internal radiation therapy (SIRT) with SIR-Spheres Y-90 resin microspheres to standard frontline FOLFOX-based chemotherapy with or without bevacizumab (Avastin) for patients with liver metastatic colorectal cancer (CRC).

Although researchers are still awaiting data on overall survival, findings thus far demonstrate that the addition improves liver disease, leading to a significant improvement in progression-free survival. This is important because, Sharma adds, this is the most common site of metastasis in patients with CRC.

Secondly, the addition of SIRT was also found to be safe and well tolerated in this patient population, Sharma explains.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x